Nasdaq · CIK 0001869105
BBOT BridgeBio Oncology Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 7 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company
Signals
Open-market buys and sells at BridgeBio Oncology Therapeutics, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 32 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Yong Ben Chief Med & Dev Officer | FTax withholding Common Stock | -1,047 | $3.94 | $4,125 | 43,529 | 7 d ago |
| Oct 1, 2026 | Idan Elmelech COO & Principal Financial Ofcr | FTax withholding Common Stock | -343 | $3.94 | $1,351 | 14,152 | 7 d ago |
| Oct 1, 2026 | Marc Cobo Principal Accounting Officer | FTax withholding Common Stock | -126 | $3.94 | $496 | 14,015 | 7 d ago |
| Oct 1, 2026 | Pedro Beltran President and CEO | FTax withholding Common Stock | -1,047 | $3.94 | $4,125 | 43,529 | 7 d ago |
| Sep 10, 2026 | Marc Cobo Principal Accounting Officer | AGrant or award Common Stock | +9,038 | $0.00 | $0 | 14,344 | 28 d ago |
| Sep 10, 2026 | Marc Cobo Principal Accounting Officer | FTax withholding Common Stock | -203 | $5.52 | $1,121 | 14,141 | 28 d ago |
| Sep 10, 2026 | Marc Cobo Principal Accounting Officer | AGrant or award Stock Option (Right to Buy)derivative | +43,700 | $0.00 | $0 | 43,700 | 28 d ago |
| Aug 26, 2025 | Frank McCormick director | AGrant or award Stock Option (Right to Buy)derivative | +91,076 | $0.00 | $0 | 91,076 | Aug 28, 2025 |
| Aug 26, 2025 | Praveen P. Tipirneni director | AGrant or award Stock Option (Right to Buy)derivative | +52,269 | $0.00 | $0 | 52,269 | Aug 28, 2025 |
| Aug 26, 2025 | Eli M. Wallace Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +499,731 | $0.00 | $0 | 499,731 | Aug 28, 2025 |
| Aug 26, 2025 | Uneek Mehra Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +633,570 | $0.00 | $0 | 633,570 | Aug 28, 2025 |
| Aug 26, 2025 | Yong Ben Chief Med & Dev Officer | AGrant or award Stock Option (Right to Buy)derivative | +357,177 | $0.00 | $0 | 357,177 | Aug 28, 2025 |
| Aug 26, 2025 | Pedro Beltran Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +357,177 | $0.00 | $0 | 357,177 | Aug 28, 2025 |
| Aug 26, 2025 | Jake Bauer director | AGrant or award Stock Option (Right to Buy)derivative | +138,193 | $0.00 | $0 | 138,193 | Aug 28, 2025 |
| Aug 11, 2025 | Bihua Chen CEO and Chairperson | MOption exercise Common Stockindirect: Via Helix Holdings II LLC | +4,172,126 | - | - | 4,681,126 | Aug 13, 2025 |
| Aug 11, 2025 | Bihua Chen CEO and Chairperson | DDisposition to issuer Common Stockindirect: Via Helix Holdings II LLC | -152,940 | $0.00 | $0 | 4,528,186 | Aug 13, 2025 |
| Aug 11, 2025 | Bihua Chen CEO and Chairperson | AGrant or award Common Stockindirect: Via Fund III | +760,496 | $10.72 | $8.2M | 2,187,536 | Aug 13, 2025 |
| Aug 11, 2025 | Bihua Chen CEO and Chairperson | AGrant or award Common Stockindirect: Via Fund V | +639,110 | $10.72 | $6.8M | 1,542,710 | Aug 13, 2025 |
| Aug 11, 2025 | Bihua Chen CEO and Chairperson | AGrant or award Common Stockindirect: Via Master Fund | +5,598,425 | $10.72 | $60M | 5,667,785 | Aug 13, 2025 |
| Aug 11, 2025 | Bihua Chen CEO and Chairperson | AGrant or award Common Stockindirect: Via Fund IV | +1,905,046 | - | - | 1,905,046 | Aug 13, 2025 |
| Aug 11, 2025 | Bihua Chen CEO and Chairperson | AGrant or award Common Stockindirect: Via Fund V | +1,762,760 | - | - | 3,305,470 | Aug 13, 2025 |
| Aug 11, 2025 | Bihua Chen CEO and Chairperson | AGrant or award Common Stockindirect: Via Master Fund | +284,571 | - | - | 5,952,356 | Aug 13, 2025 |
| Aug 11, 2025 | Bihua Chen CEO and Chairperson | DDisposition to issuer Class B ordinary sharesderivativeindirect: See footnote | -307,874 | $0.00 | $0 | 4,172,126 | Aug 13, 2025 |
| Aug 11, 2025 | Bihua Chen CEO and Chairperson | MOption exercise Class B ordinary sharesderivativeindirect: See footnote | -4,172,126 | - | - | 0 | Aug 13, 2025 |
| Aug 11, 2025 | Mark C. McKenna other | MOption exercise Common Stock | +30,000 | - | - | 30,000 | Aug 11, 2025 |
| Aug 11, 2025 | Albert A Holman III other | MOption exercise Common Stock | +30,000 | - | - | 30,000 | Aug 11, 2025 |
| Aug 11, 2025 | John P. Schmid other | MOption exercise Common Stock | +30,000 | - | - | 30,000 | Aug 11, 2025 |
| Aug 11, 2025 | Albert A Holman III other | MOption exercise Class B ordinary sharesderivative | -30,000 | $0.00 | $0 | 0 | Aug 11, 2025 |
| Aug 11, 2025 | Mark C. McKenna other | MOption exercise Class B ordinary sharesderivative | -30,000 | $0.00 | $0 | 0 | Aug 11, 2025 |
| Aug 11, 2025 | John P. Schmid other | MOption exercise Class B ordinary sharesderivative | -30,000 | $0.00 | $0 | 0 | Aug 11, 2025 |
| Feb 8, 2025 | Bihua Chen CEO and Chairperson | JOther Class B Ordinary Sharesderivativeindirect: See Footnote | -30,000 | $0.00 | $0 | 4,480,000 | Feb 10, 2025 |
| Feb 8, 2025 | Helix Holdings II LLC director, owner | JOther Class B Ordinary Sharesderivative | -30,000 | $0.00 | $0 | 4,480,000 | Feb 10, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Jake Bauerdirector
- Pedro BeltranChief Scientific Officer
- Yong BenChief Med & Dev Officer
- Bihua ChenCEO and Chairperson
- Marc CoboPrincipal Accounting Officer
- Idan ElmelechCOO & Principal Financial Ofcr
- Helix Holdings II LLCdirector, owner
- Albert A Holman IIIother
- Frank McCormickdirector
- Mark C. McKennadirector, other
- Uneek MehraChief Financial Officer
- John P. Schmiddirector, other
- Praveen P. Tipirnenidirector
- Eli M. WallaceChief Executive Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.